Genís Oña · Journal of Psychedelic Studies 2026 · non-systematic historical literature review · n=?

The long roots of ibogaine: A journey from plant to pharmaceutical

Cited 0 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Level 5 by design analogy for a narrative historical literature review

OpenAlex W7134229554 · doi:10.1556/2054.2026.00491 · record verified 2026-08-28

What was done

The authors conducted a non-systematic historical literature review evaluating the development of ibogaine prior to the 1960s. Using a postcolonial historiographical approach examining colonial botany, biopiracy, and intellectual property, the review analyzed three phases: French colonial acquisition and classification of iboga in the Congo Basin, the alkaloid's isolation in 1900 with subsequent early French pharmaceutical research, and the international commercialization of ibogaine-containing retail formulations.

What was found

The investigation identified multiple historical retail medicines containing ibogaine beyond Lambarène, specifically Dragées Nyrdahl, Grains des Anémiques, Syséros, Viris Lucet, Ibobiose, and Iperton. The review uncovered discounted records of local indigenous use in the Congo Basin that guided early-to-mid 20th-century medical research, as well as historical documentation showing ibogaine was used in Mexico in 1913 for treating a substance use disorder. The abstract reports no quantitative clinical metrics or numerical data.

Why it matters

The findings challenge dominant narratives that attribute the discovery of ibogaine's anti-addictive properties solely to Howard Lotsof in the 1960s, documenting prior application in 1913. It contextualizes modern pharmaceutical interest within historical colonial extraction and indigenous knowledge systems.

Limits

The study is a non-systematic historical review subject to selection and archival retrieval biases. The abstract does not quantify the number of sources reviewed and presents no quantitative clinical efficacy, pharmacokinetic, or safety outcome data.

Cited by